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Role of atrial natriuretic factor in volume control. Atrial natriuretic
factor (ANF) is a 28 amino acid polypeptide hormone secreted mainly by
the heart atria in response to atrial stretch. ANF acts on the kidney to
increase sodium excretion and GFR, to antagonize renal vasoconstriction,
and to inhibit renin secretion. In the cardiovascular system, ANF antag-
onizes vasoconstriction, and shifts fluid from the intravascular to the
interstitial compartment. In the adrenal gland, ANF is a powerful inhibitor
of aldosterone synthesis. ANF participates importantly in the natriuretic
response to acute and chronic volume overload. ANF's property of
shifting fluid from the vascular to the interstitial compartment acts as a
buffering device, guarding against excessive plasma volume expansion in
face of an increased total extracellular fluid volume. ANF is also a
physiological modulator of GFR, and mediates nephron hyperfiltration
and natriuresis when salt excretion is threatened by a reduction in the
number of nephrons. Guanylyl cyclase (GCA) receptors mediate the
effects of ANF by generating cGMP. Clearance receptors remove ANF
from the circulation by receptor-mediated endocytosis, and serve as a
hormone buffer system to impede large inappropriate fluctuations in
plasma levels of ANF. The specific structure-function-dynamics relation-
ships of these receptors serve to modulate the role of ANF in pressure-
volume homeostasis.
In 1981 de Bold et al published the decisive experiment
demonstrating that administration of a crude acid extract of rat
atria to anesthetized rats led to a powerful natriuretic response,
sodium excretions increasing more than fortyfold above baseline
levels, whereas a similarly prepared ventricular extract was with-
out effect [fl. The natriuretic substance(s) was named atrial
natriuretic factor (ANF). Our studies in the isolated perfused rat
kidney demonstrated that the natriuretic effect of atrial extract is
due in part to its direct actions on the kidney. Atrial extract
increased GFR, constricted efferent arterioles, and had unique
renal vascular action, acting as a powerful antagonist of vasocon-
striction with a small agonist (vasoconstrictive) action of its own
[2]. Studies with atrial extract were short lived because by the end
of 1983 and early 1984 several laboratories, including our own,
purified ANF to completion, and determined its chemical struc-
ture [31. Since then there has been a veritable explosion of
research in the field, with more than 6,000 articles published to
date. In this article I will briefly describe the main properties and
the functions of ANF and its receptors in effecting volume
regulation. For an inclusive recent review on ANF and its
receptors, with extensive literature citations, the reader is directed
to [3].
The chemical nature of ANF
As shown in Figure 1, ANF is a polypeptide hormone of 28
amino acids (ANF28) with a core sequence between disulfide
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linked cysteines, and a C terminal extension that confers biolog-
ical activity to the peptide [31. Among different mammalian
species, ANF differs by a single amino acid in position 12, such as
isoleucine in the rat, methionine in humans [3]. ANF is a member
of an ever growing family of so-called natriuretic peptides with a
conserved central core and variable N and C terminal sequences
(Fig. 1). Brain natriuretic peptide (BNP), in spite of its name, is
present at the highest concentration in atrial and ventricular
muscle. In normal conditions, the concentrations of BNP in heart
tissue and plasma are far lower that those of ANF. However, in
ventricular hypertrophies the expression of this peptide increases
and may reach levels similar to those of ANF. BNP shares the
same receptors and have the same effects as ANF when adminis-
tered to experimental animals. C-type natriuretic peptide (CNP)
is present mostly in brain and in endothelial cells, and in spite of
its name, it does not have significant natriuretic activity in
mammals. ANF 32, better known as urodilatin, has been detected
in urine and distal tubular cells. When administered to mammals,
urodilan tin effects are undistinguishable from those of ANF. The
physiological roles of BNP, CNP and urodilatin are essentially
unknown, and these peptides will not be further considered in this
short review.
The main effects of ANF in the mammalian organism
Figure 2 schematically illustrates the main effects of ANF in
mammalian organisms. The stimulus for the secretion of ANF is
atrial stretch or pressure. Thus, increases in plasma volume, and
systemic and pulmonary pressures are the physiologic stimuli for
ANF secretion. The main actions of ANF are: (i) direct and
indirect effects on the kidney to alter renal hemodynamics, and to
increase fluid and electrolyte excretion; (ii) functional antagonism
of the renin-angiotensin-aldosterone system by inhibiting synthe-
sis and/or release of renin and aldosterone, and by antagonizing
all known effects of angiotensin; (iii) functional antagonism to all
modalities of humoral or autonomic induced vasoconstriction;
and (iv) shift of fluid from the intravascular to the interstitial
compartment by increasing capillary hydraulic permeability. It is
not difficult to surmise that these combined effects of ANF are
essentially geared to regulate pressure-volume homeostasis.
Renal actions of ANF
Figure 3 schematically illustrates the several nephron sites that
are targets for ANF effects (a detailed review and specific
references are in [3]). ANF increases single nephron (SN) GFR in
proportion of total GFR. The increase in GFR is due mainly to an
increase in glomerular capillary hydrostatic pressure that results
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ANF (ANF 28) and other members of the natriuretic peptide family. The peptides have a conserved central core between
disulfide linked cysteines (shaded) and variable C and N terminals. See text for details.
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from efferent artcriolar constriction and afferent arteriolar dila-
tion. In normal conditions, ANF does not alter or even slightly
decreases SN and total renal blood flow (RBF). ANF is the only
known endogenous substance that may increase GFR in face of a
decrease in blood pressure, and an unchanged or even decreased
RBF. In vasoconstricted kidneys, however, ANF markedly in-
creases RBF due to its generic vasorelaxant property (see below).
ANF markedly increases the load of sodium to the base of the
inner medullary collecting duct (IMCD), an effect that is essential
Fig. 2. The main actions of ANF in the
mammalian ofrganism. See text for description.
Abbreviations are: VSM, vascular smooth
muscle; IVF, intravascular fluid volume; IF,
interstitial fluid volume.
for a robust natriuretic response, and subsequently disrupt load-
reabsorption balance in this nephron segment. The reasons for
the increase in sodium load to the IMDC are multiple, and
include: (i) increase in GFR; (ii) decrease in inner medullary
hypertonicity that decreases passive fluid efflux from the thin
limbs of Henle's loop; (iii) direct tubular effects of ANF that
decrease sodium reabsorption in nephron segments proximal to
the IMDC. The disruption of load-reabsorption balance in the
IMDC also has multiple causes, including a decrease in sodium
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Fig. 3. Postulated nephron sites of action of ANF. 1. Increase in GFR by
constriction of efferent arterioles (EA) and dilation of afferent arterioles
(AA). 2. Inhibition of Na reabsorption in deeper nephron proximal
convoluted tubules (PCT). 3. Inhibition of angiotensin-stimulated Na
reabsorption. 4. Increase in sodium load to descending limb of Henle's
loop (DHL). 5. Decrease in hypertonicity and increase in pressure in inner
medullary interstitium. 6. Decrease in passive water efflux from DHL. 7.
Decrease in passive Na reabsorption from thin ascending limb (AHL). 8.
Increase in Na load to thick ascending limb (TAL) and macula densa
(MD). 9. Inhibition of renin Secretion. 10. Inhibition of sodium reabsorp-
tion in distal tubule (DCT) and cortical collecting duct (CCT) by
ANF-induced inhibition of aldosterone secretion. 11. Inhibition of thia-
zide-sensitive NaCI reabsorption. 12. Increase in Na load to the inner
medullary collecting duct (IMDC). 13. Inhibition of amiloride-sensitive
Na reabsorption. 14. Increase in Na influx by stimulation of Na-K-2C1
cotransport and passive forces. Reproduced with permission from Oxford
University Press [31.
efflux by inhibition of an amiloride-sensitive cation channel, and
an increase in sodium influx by stimulation of a basolateral
furosemide-sensitive Na-K-2Cl cotransporter, and by an in-
crease in pressures in the inner medullary interstitium. Because
ANF is a powerful inhibitor of the renin-angiotensin-aldosterone
system, it will indirectly act on tubular sites that are targets of this
system, including proximal tubular sites (angiotensin) and distal
nephron sites (aldosterone).
Although the relative contribution of each of the nephron
actions of ANF to its final natriuretic action remains to be
elucidated, it is clear that hemodynamic factors, including but not
limited to the increase in GFR, are paramount for a robust
natriuretic response. We and others have demonstrated that when
renal hemodynamic effects are precluded by early and late renal
clamp experiments in dogs or rats, ANF fails to elicit an important
increase in sodium excretion [31. Abnormal renal hemodynamics
explain to a great degree, if not totally, the resistance of the kidney
to the natriuretic effect of endogenous or administered ANF in
some pathological cases of volume retention such as congestive
heart failure or the nephrotic syndrome.
ANF and the renin-angiotensin-aldosterone system
ANF infusion markedly inhibits renin secretion by the kidney
and aldosterone secretion by the adrenal, resulting in a decrease
in plasma levels of these antinatriuretic hormones [4, 5]. The
decrease in plasma aldosterone is due to the decrease in plasma
renin activity, and to a direct effect of ANF on adrenal zonal
glomerulosa to inhibit aldosterone synthesis. The most likely
explanation for the decrease in renin secretion is the increase in
sodium load to the macula densa, as ANF fails to decrease renin
when the increase load to the macula densa is impeded, such as in
renal clamp experiments [31. ANF also antagonizes all of the
known effects of angiotensin II, including its peripheral vasocon-
strictive effect, its growth promoting activity in vascular smooth
muscle cells, its stimulation of proximal sodium fluid reabsorp-
tion, and its central dipsinogenic effect [3]. These antagonistic
effects are likely due to the ANF-induced decrease in cytosolic
calcium that, at least in vascular smooth muscle cells, is due to
cGMP-dependent stimulation of sarcolemmal Ca2 ATPase ac-
tivity.
The physiological importance of the inhibition of the renin-
angiotensin-aldosterone system for the overall role of ANF in
volume control has been suggested by results of a dose-effect
study in humans [3]. In this study, ANF infusion at rates that
barely increased plasma levels of the hormone, and led to only
slight, if any, increase in fluid and electrolyte excretion, markedly
decreased plasma renin activity and plasma aldosterone levels.
Maximal inhibition was obtained at lower doses than those
needed for a maximal natriuretic and diuretic effect.
ANF and cardiovascular hemodynamics
The effects of ANF on cardiovascular hemodynamics are com-
plex and depend on the status of cardio-circulatory parameters.
Administration of ANF decreases blood pressure slightly but
consistently in normotensive experimental animals and humans,
and markedly in several models of hypertension in laboratory
animals [3]. In normotension, ANF decreases blood pressure by
decreasing cardiac output (CO), while calculated total peripheral
resistance remains unaffected [6]. ANF decreases CO by lowering
plasma volume and central venous pressure, the decrease in
plasma volume being due to a shift of fluid from the intravascular
to the interstitial compartment (see below) [5, 7]. Similarly, in
experimental models of volume-dependent hypertension (such as
DOC-salt hypertension in rats), the ANF-induced decrease in
blood pressure is due mainly to a decrease in CO. However, in
renin-dependent models of hypertension (such as 2K-iC, Gold-
blatt hypertension in rats), ANF decreases blood pressure mainly
by counteracting the vasoconstriction, and CO may be even
slightly increased due to the relieve in afterload [3]. From the
studies referred to above, and from our earlier studies in the
isolated perfused rat kidney [2], it is clear that ANF is not a
vasodilator in a strict sense, but an antagonist of vasoconstriction.
This property, together with the effect of ANF on the redistribu-
tion of extracellular fluid volume (see below), explains to a great
extent the complex and sometimes apparently contradictory effect
of ANF on cardiovascular dynamics.
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ANF and the distribution of extracellular fluid volume
In experiments in anesthetized dogs in 1984, we demonstrated
that after the administration of ANF, hematocrit rose in spite of
religious replacement of external fluid losses. We postulated then
that ANF may shift fluid from the intravascular to the interstitial
compartment [5]. The definitive proof of this unique effect of
ANF came from experiments in nephrectomized rats, in which
administration of ANF leads to a significant decrease in blood
pressure, an increase in hematocrit and a corresponding decrease
in plasma volume. Sodium nitroprusside, at doses that decrease
blood pressure to the same degree as ANF, did not cause a change
in hematocrit or plasma volume, demonstrating that these effects
of ANF were not due to a redistribution of fluid induced by the
decrease in blood pressure [71. These findings were confirmed by
several groups of investigators, and subsequent experiments in
isolated mesenteric capillaries demonstrated conclusively that
ANF markedly increases capillary hydraulic permeability leading
to an efflux of fluid without changes in net ultrafiltration forces [81.
In the lung, ANF may be having a protective effect against the
edema because an increase in hydraulic permeability in the low
pressure lung capillaries will favor absorption rather than filtra-
tion of fluid.
The physiological importance of this unique effect of redistrib-
uting extracellular fluid volume is illustrated by the results of a
very recent study using an ANF knockout mouse model. In this
study heterozygous animals, which have approximately one-half
the plasma concentration of ANF compared to normal mice,
already had a significantly decreased hematocrit, in spite of
normal salt excretion. The hematocrit was further decreased in
homozygous animals with no detectable ANF in plasma [9].
Role of ANF in adaptive increases in GFR and
sodium excretion
Until recently, in spite of the compelling evidence partially
described above, the physiological role of ANF as a modulator of
GFR, and the participation of the hormone in volume homeosta-
sis has been questioned. Recently, Matsuda and Morishita devel-
oped a specific non-peptidic GC receptor antagonist with which to
reinvestigate these fundamental issues. The antagonist named
HS-142-1, competes with ANF for binding to the guanylyl cyclase
(GC) receptors, and does not affect ANF binding to clearance
receptors. HS-142-I does not have any known action of its own,
and antagonizes all known cardiovascular, renal and adrenal
effects of the hormone [10].
in conscious and anesthetized rats fed a normal or a high salt
diet, but not a low salt diet, administration of HS-142-1 signifi-
cantly decreases GFR, demonstrating that ANF is necessary to
maintain a normal level of glomerular filtration [11, 121. The lack
of effect of HS-142-1 on GFR in rats fed a low salt diet, an
experimental condition characterized by very low plasma levels of
ANF, further attests to the specificity of the GC receptor antag-
onist in blocking the GFR modulatory role of this hormone [12].
Moreover, HS-142-1 blocked the hyperfiltration in the remnant
kidney after 4/5 nephrectomy, and the hyperfiltration in streptoto-
zin-induced diabetes in rats, demonstrating that ANF plays an
important role in the adaptive increases in GFR in compensatory
glomerular hypertrophy [12, 131.
Use of HS-142-1 and of the ANF knockout mouse model also
furthered our understanding of the role of ANF in the adaptation
to experimentally-induced volume expansion and high salt intake.
Thus, HS-142-1 markedly blunted the natriuresis of acute saline
expansion, and the natriuresis of mineracorticoid escape phenom-
enon [10, 14]. Moreover, in the homozygous ANF knockout
mouse, with no detectable plasma levels of ANF, adaptation to a
high salt diet was impaired, resulting in "salt-sensitive" hyperten-
sion [9].
The recent studies described above provide unequivocal evi-
dence that ANF is significantly involved in the physiological
modulation of GFR, and that ANF has a significant role in the
natriuretic response to acute volume expansion. Perhaps more
important, these studies show that ANF is not simply an "emer-
gency" hormone involved in the response to acute volume over-
load, as has been assumed by some investigators, but that it has a
significant role in the adaptation to chronic volume expansion.
Furthermore, ANF is significantly involved in the adaptations of
renal functions, including maintenance of total GFR, when ade-
quate salt excretion is threatened by a loss in the number of
functioning nephrons.
Receptor functions and dynamics modulate ANF actions
There are two biochemically and functionally distinct classes of
ANF receptors whose structure-function-dynamics characteristics,
schematically represented in Figure 4, effect the role of ANF in
pressure-volume homeostasis [3, 15, 16]. The cytoplasmic domain
of GC receptors contains a guanylyl cyclase sequence and a
"kinase-like" sequence that modulate the activity of guanylyl
cyclase [16]. Thus the GC receptor is unique as it contains in a
single molecule the acceptor (ligand binding sites), effector (gua-
nylyl cyclase), and modulator (kinase-like domain) functions. The
GC receptor is a bonafide membrane resident protein that does
not undergo rapid endocytosis. When GC receptors are unoccu-
pied, the kinase-like domain represses the activity of guanylyl
cyclase. ANF binding derepress the guanylyl cyclasc moiety,
leading to the generation of cGMP, the main if not sole messenger
of all known actions of ANF [16]. This event is accompanied by
loss of receptor affinity, resulting in a very rapid receptor-ligand
dissociation [17]. Thus, GC receptors function in a "staccato"
mode with very rapid ligand on and off rates. The rapid associa-
tion of ANF with GC receptors, together with the presence of the
acceptor-effector-modulator functions in a single receptor mole-
cule, allows for immediate and powerful responses upon increases
in plasma levels of ANF. The extremely rapid receptor-ligand
dissociation leads to the prompt termination of responses when
plasma levels of ANF fall.
Plasma levels of ANF are determined by the balance between
its rate of secretion by the atria, and its metabolic clearance rate
at peripheral tissues. A specific class of ANF receptors, appropri-
ately named clearance (C) receptors, is responsible for the fast
metabolic clearance and very short plasma half-life (ito 3 mm) of
the hormone [18, 191. Structurally, C receptors have a very short
cytoplasmic domain (37 amino acids), a characteristic feature of
all clearance and/or transport receptors described to date [15]. C
receptors do not mediate any of the known cardiovascular, renal
and adrenal effects of ANF described in this review. Accordingly,
in vivo blockade of C receptors by specific ligands decreases the
metabolic clearance of endogenous ANF resulting in elevated
plasma levels of the hormone [15, 18]. The mechanism of the
clearance function of C receptors is by receptor-mediated endo-
cytosis and delivery of ANF to lysosomes where it is hydrolyzed to
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completion, while the internalized receptors are recycled to the
cell surface (Fig. 4) [20]. ANF dissociates very slowly from surface
C receptors, resulting in sufficient resident time for the endocy-
tosis of receptor-ligand complexes [15]. Thus, C receptors func-
tion in a "continuo" mode, continuously delivering ANF to
lysosomes, and returning to the cell surface to mediate additional
cycles of removal of ANF from the circulation. In this manner, C
receptors act as a hormone buffer system to impede large and
inappropriate plasma fluctuations of ANF, to rapidly bring plasma
levels of ANF to basal levels once the stimulus for its secretion
ceases, and to dispose of ANF molecules dissociated from GCA
receptors. The combination of the "staccato" and "continuo"
modes of GC and C receptor functions, respectively, allows for a
precise modulation of the role of ANF in pressure-volume
homeostasis.
The two arms of the participation of ANF in volume control
Under normal conditions, the role of ANF in the regulation of
extracellular fluid and plasma volume is brought about by the two
arms of its action. On one hand, ANF increases renal sodium
excretion by its direct actions of the kidney, and by inhibiting
secretion and end-organ effects of antinatriuretic hormones,
particularly angiotensin and aldosterone. On the other hand, ANF
decreases plasma volume by shifting fluid from the vascular
compartment. This action helps to relieve—albeit incompletely—
the increase in plasma volume brought about by an increase in
total salt content and extracellular fluid volume. In the presence
of enhanced antinatriuretic impulses, and abnormal renal hemo-
dynamics, such as in congestive heart failure or in the nephrotic
syndrome, the excretory arm of ANF's role is markedly blunted
but its buffering effect on plasma volume may remain intact. In the
last instance, the major physiological role of ANF is to defend
against excessive plasma volume expansion, even at the cost of a
relative expansion of the interstitial fluid volume.
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